Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide and Active Vitamin D in Osteoporosis
NCT01430104Phase 4
Key facts
- Status
- Completed
- Start
- Aug 2011
- Primary completion
- Dec 2011
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Drugs
- teriparatide
- Conditions
- osteoporosis
01
Overview
Phase 4, open-label trial of teriparatide in osteoporosis, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Serum Calcium Level Over 11.0 Milligrams Per Deciliter at Day 28. Started Aug 2011; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Ambulatory Japanese males or postmenopausal females with osteoporosis, excluding those with prior PTH treatment, recent bisphosphonate use, or history of metabolic bone disorders other than primary osteoporosis.
04
Endpoints
Primary
Number of Participants With Serum Calcium Level Over 11.0 Milligrams Per Deciliter
Beyond the preview
Go deeper on NCT01430104.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01430104.